Parikh SV

Department of Psychiatry, University of Michigan, Ann Arbor, USA.

5 papers

ArticleKetamine

Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial.

Singh B, MahmoudianDehkordi S, Vande Voort JL +9

Europe PMC2026
ArticleKetamine

DATAd: A new communication and tracking system for treatment-resistant depression.

Conroy SK, Voytenko VL, Docherty AR +6

Europe PMC2026
ArticleKetamine

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Wilkinson ST, Prashad S, Dalthorp R +10

Europe PMC2026
ArticleKetamine

Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.

Penaluna BK, Vande Voort JL, Bobo WV +7

Europe PMC2025
ArticlePsilocybin

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.

Rosenblat JD, Husain MI, Lee Y +18

Europe PMC2023